{rfName}
De

Indexed in

Altmetrics

Analysis of institutional authors

Torres Benitez, FerranAuthorRios Guillermo, Jose PedroAuthorMaduell, FranciscoCorresponding Author

Share

August 13, 2024
Publications
>
Article
No

Design and patient characteristics of ESHOL study, a Catalonian prospective randomized study

Publicated to: Journal Of Nephrology. 24 (2): 196-202 - 2011-03-01 24(2), DOI: 10.5301/JN.2010.386

Authors:

Maduell, Francisco; Moreso, Francesc; Pons, Mercedes; Ramos, Rosa; Mora-Macia, Josep; Foraster, Andreu; Soler, Jordi; Galceran, Josep M; Galceran, Josep M; Martinez-Castelao, Alberto
[+]

Affiliations

CETIRSA, Barcelona, Spain - Author
Diaverum Baix Llobregat, Lhospitalet De Llobregat, Spain - Author
Fresenius Med Care, Granollers, Spain - Author
Fresenius Med Care, Reus, Spain - Author
Fundació Althaia, Manresa, Spain - Author
Hosp Clin Barcelona, Serv Nefrol & Trasplante Renal, Dept Nephrol, ES-08006 Barcelona, Spain - Author
Hosp San Antonio Abad, Dept Nephrol, Vilanova I La Geltru, Spain - Author
Hosp Univ Bellvitge, Dept Nephrol, Barcelona, Spain - Author
Hosp Univ Vall dHebron, Dept Nephrol, Barcelona, Spain - Author
See more

Abstract

Background: Retrospective studies showed that online hemodiafiltration (OL-HDF) is associated with a risk reduction of mortality over standard hemodialysis (HD) in patients with end-stage renal disease. Until now, no information was available from prospective randomized clinical trials. Methods: A prospective, randomized, multicenter, open study was designed to be conducted in HD units from Catalonia (Spain). The aim of the study is to compare 3-year survival in prevalent end-stage renal disease patients randomized to OL-HDF or to continue on standard HD. The minimum sample size was calculated according to Catalonian mortality of patients on dialysis and assuming a risk reduction associated with OL-HDF of 35% (1-sided p
[+]

Keywords

Convective therapiesDialysisDialysis adequacyEsrFlux hemodialysisMortalityMortality riskOn-line hemodiafiltratioOn-line hemodiafiltrationOnline hemodiafiltrationPatients receiving hemodiafiltration

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal JOURNAL OF NEPHROLOGY due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2011, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Nephrology. Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Urology & Nephrology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-01:

  • WoS: 16
  • Scopus: 17
  • Europe PMC: 13
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-01:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 39 (PlumX).
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Maduell Canals, Francisco) .

the author responsible for correspondence tasks has been Maduell Canals, Francisco.

[+]

Awards linked to the item

Financial support: This study was partly supported by grants from Fresenius Medical Care and Gambro Healthcare.
[+]